Excited to see our paper in print @EUplatinum: https://t.co/9G6F1Q2Q5y Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

Marshall talks about joy in collaboration throughout his career starting with the development of the Stoller Afferent Nerve Stimulator aka PTNS @UCSFUrology Grand Rounds

In a trial of men with suspected prostate cancer, biparametric MRI, which excludes the gadolinium contrast sequence, was noninferior to multiparametric MRI for detecting clinically significant cases. 🧵 https://t.co/t4f6t0k1uF

Thanks to @UCSFCancer for covering our study which showed that a PPARg agonist rosiglitazone (an old diabetes drug) can modulate NECTIN4 & enhance activity of a new CAR T in #bladdercancer @CChuMD @koshkin85 @DrTFriedlander @SimaPorten @UCSFUrology

Research funded in part by BCAN with @jonchou05 in @NatureComms : Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Click here to read the article:

Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.

Alliance researcher @eugene_pietzak @MSKCancerCenter leads @ALLIANCE_org A032303/GAIN-BCG, a trial evaluating a two-step treatment approach for pts w/BCG-unresponsive non–muscle-invasive #bladdercancerome. Learn more: https://t.co/mjpt3I0t2n #NCI #NCTN #CancerResearch #NMIBC

Palliative care is about more than end-of-life - it’s about quality of life. Drs. Pauline Filippou & Ashwin Kotwal join @GMBadalato & @lindsayahampson to discuss why palliative care belongs in urology & how to integrate it into everyday practice #URO249 https://t.co/tDPPjMFgZK

🚨New in @EUPlatinum! 📌 PSMA PET for Prostate Cancer Diagnosis & Staging by @elio_mazzone et al 🧠 This comprehensive meta-analysis confirms the high diagnostic value of PSMA PET—especially when combined with MRI—but reminds us it’s not enough to skip biopsy or lymph node

Congratulations to @arihakimi who was chosen unanimously by the class of 2025 Urologic Oncology Fellows as Teacher of the Year. Well deserved! @MTDawidek @MariaPereMD @sunny_nal @therealUroJET @UroMuneeb

Congrats to Kevin Shee for matching into the UCSF UroOnc SUO fellowship program! @KShee11 #UroOnc #SUO #SUOMatch

New review on urothelial carcinoma highlights therapeutic & diagnostic approaches in the perioperative setting, emphasizing patient‐centered & individualized care. https://t.co/UmeZIAumxa @WesleyYipMD @SalvadorjcMD @KothariAnjaney @domesypantsx3 @AnneSchuckmanMD @DrRosenbergMSK

Thanks for welcoming the second generation Feng to ASCO! What’s your #ASCO25 happy dance? @DrChoueiri @nlinmd @DrKarenKnudsen @DrPaulNguyen @APDicker @EdwinPosadasMD @DrKatePedersen @JoshLangMD @PamelaKunzMD @fumikochino

Now published in @JUrology by @UrologyMSK Sherri Donat, @eugene_pietzak, @EKChaMD, @bca_md, @bbmdmsk, @alvincgoh et al: Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted Radical Cystectomy With Intracorporeal Ileal Conduit https://t.co/99NG8kKA1B

@JoeBiden @SocialSecurity @theNCI @CNN @lkayat @jeshoag @MUSICUrology @jimhumd @TylerSbrt 12/12 Summary, men >70yo absolutely can benefit from personalized screening. A) Comorbidities/life expectancy should be estimated B) PSA should be used to guide screening based on A C) MRI should be used based on A and B D) Biopsy should be used based on A-C -Observation or PSA

Excited to share our latest work, now out in European Urology! We followed >166k prostate cancer survivors (1999–2019) using SEER-Medicare. RP+EBRT had the highest risk of urinary adverse events. EBRT surpassed RP at 10 yrs (with BT) & 14 yrs (alone). https://t.co/GyqW2GmAWl

UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡@bcan_chisolm @UCSFCancer @UCSFUrology @SimaPorten @jonchou05 @koshkin85 @SamWashUro

Revolutionizing #ProstateCancer care! @CChuMD @UCSFUrology presents on the crucial role of PSMA PET in surgical planning & post-op management, highlighting preoperative staging, intraoperative guidance with PSMA-conjugated fluorophore IS-002, and biochemical recurrence

My favorite GR - graduating chief residents discuss their projects from their research year

1/2 POTOMAC is the last of the 15 PD(L)1 monotherapy IO R3 trials over 10yrs & >8000 pts in bladder cancer. The summary shows 1)clearer activity in earlier disease 2)the biomaker failing 3)PD-L1 & PD1 targeting having equal success 4)An unidentified subset respond in all settings

A mentee’s success is 100x better than your own. Congratulations @IlanoArielle on her Dean’s Prize for work with @UCSFUrology, as well as upcoming graduation from @UCSFMedicine, and match with @UCSFAnesthesia. 🌟🌟 @ben_breyer @AShindelGHI @lindsayahampson @pcarroll_